SS-31 Peptide: The Mitochondrial Longevity Angle Explained

Most longevity peptides act on signalling: growth hormone secretagogues, NAD precursors, senolytics. SS-31 is different. It is a four-amino-acid peptide that physically anchors itself to a phospholipid called cardiolipin on the inner mitochondrial membrane, and as of September 2025 it became the first mitochondria-targeted peptide ever approved by the FDA. This guide walks through the mechanism, the clinical record (including where trials missed their primary endpoints), and what the aging research actually supports.

Key takeaways#

• SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) developed by the Szeto-Schiller group at Cornell that binds cardiolipin in the inner mitochondrial membrane and stabilises cristae architecture.
• The FDA granted accelerated approval to elamipretide (brand name Forzinity) on 19 September 2025 for Barth syndrome, making it the first approved mitochondria-targeted peptide in history.
• In a randomised placebo-controlled trial in 39 older adults aged 60-85, a single dose improved skeletal muscle mitochondrial ATP production and fatigue resistance.
• The PROGRESS-HF Phase 2 trial in heart failure with reduced ejection fraction missed its primary endpoint at 4 weeks, illustrating that mechanistic promise does not automatically translate to clinical outcomes.
• SS-31 is not sold by Klarovel. Research-grade material is available from specialised suppliers; the FDA-approved formulation is restricted to diagnosed Barth syndrome patients weighing at least 30 kg.

Why cardiolipin is the right target for mitochondrial aging#

Cardiolipin is a phospholipid found almost exclusively on the inner mitochondrial membrane, and it holds the architecture of the electron transport chain in place. When cardiolipin oxidises or remodels poorly (as happens with aging and in genetic disorders like Barth syndrome), the respiratory chain supercomplexes destabilise, ATP output falls, and reactive oxygen species production climbs.

SS-31 was engineered to solve exactly this problem. Elamipretide localizes to the inner mitochondrial membrane and binds to cardiolipin via electrostatic interactions due to its positively charged amino acid residues. This binding stabilizes cardiolipin, preventing oxidative damage and maintaining respiratory chain integrity. Mechanistic work published in 2025 confirms that elamipretide binds to cardiolipin on the inner mitochondrial membrane, stabilizing respiratory chain supercomplexes, enhancing electron transport efficiency, and reducing reactive oxygen species production .

The selectivity is what makes it interesting. Despite their strong positive charge density (formal charge of +3), exogenously added SS peptides traverse the plasma membrane in an energy-independent and non-saturable manner, and accumulate strongly (1000 to 5000-fold) at the mitochondrial inner membrane . A peptide that concentrates a thousand-fold at the exact organelle responsible for cellular energetics is, in mechanistic terms, an unusually clean tool.

Research suggests this is not classical antioxidant activity. Early studies inaccurately described ELAM as having antioxidant properties, although more recent work has demonstrated that ELAM actually decreases production of superoxide and H₂O₂ particularly where overproduction resulted from dysfunctional mitochondria . The peptide reduces ROS at the source by restoring electron transport efficiency, not by scavenging free radicals after the fact.

The FDA approval changed the regulatory landscape#

For two decades, mitochondria-targeted peptides existed in a clinical limbo: promising preclinical data, sprawling trial programs, no approvals. That changed in autumn 2025.

On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide, the first therapy directly targeting the mitochondrial etiology of BTHS (Barth syndrome). According to Stealth BioTherapeutics, FORZINITY was granted accelerated approval by the U.S. Food & Drug Administration (FDA) in September 2025 as the first FDA-approved treatment for Barth syndrome, as well as the first FDA-approved mitochondria-targeted therapeutic .

The approval is narrow. The Food and Drug Administration (FDA) has granted accelerated approval to Forzinity™ (elamipretide HCl) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30kg . Barth syndrome is genuinely rare: Barth syndrome occurs primarily in males and is estimated to affect one in 1,000,000 male births or around 150 known individuals in the United States .

The approval pathway also tells you something honest about the evidence base. Findings showed treatment with elamipretide did not statistically significantly improve distance walked during the 6-minute walk test and total fatigue score on the Barth syndrome assessment compared with placebo (primary endpoints). While increases in knee extensor muscle strength were not observed during the randomized trial, improvement was seen during the open-label extension period. The accelerated approval rested on knee extensor strength as an intermediate endpoint, with confirmatory clinical benefit still to be verified. Read the FDA integrated review and the PubMed summary of the approval for the regulatory specifics.

This matters for longevity framing. Approval validates that cardiolipin binding produces measurable functional improvement in a population with profound cardiolipin dysfunction. It does not yet validate the broader anti-aging claims that often appear in wellness marketing.

What the aging-muscle trial actually showed#

The most relevant study for a longevity audience is the single-dose elamipretide trial in older adults. The design was rigorous and the cohort was specifically selected for the problem the peptide is meant to address.

Here, we describe the impact of a first-in-class cardiolipin-binding compound that is targeted to mitochondria and improves oxidative phosphorylation capacity (Elamipretide, ELAM) in a randomized, double-blind, placebo-controlled clinical trial. Non-invasive magnetic resonance and optical spectroscopy provided measures of mitochondrial capacity (ATPmax) with exercise and mitochondrial coupling (ATP supply per O2 uptake; P/O) at rest. The first dorsal interosseous (FDI) muscle was studied in 39 healthy older adult subjects (60 to 85 yrs of age; 46% female) who were enrolled based on the presence of poorly functioning mitochondria.

A single subcutaneous dose improved in vivo ATP production and coupling in skeletal muscle. The full results are published in the PMC open-access record. This is preliminary evidence that cardiolipin stabilisation produces measurable bioenergetic improvement in healthy older humans, not just in disease populations.

The mouse data points in the same direction. Chronic ELAM administration (8 weeks to 48 weeks) increases exercise tolerance, muscle mass, fatigue resistance, and in vivo ATPmax. Other studies have shown beneficial effects on cardiac diastolic function in aging mice. Crucially, a 2025 Aging Cell paper added important nuance: elamipretide restores cardiac and skeletal muscle performance in aged mice by improving mitochondria and reducing inflammation. Elamipretide improved physical function in aged mice without lowering biological age, which was estimated using molecular markers in DNA and gene activity.

Translation: the peptide is associated with improved physical function, but it does not appear to reset epigenetic age. It is a functional intervention, not a chronological clock reset.

The heart failure data is more complicated#

If you read marketing copy on SS-31, you will see confident claims about cardiac protection. The actual Phase 2 record is more mixed. The PROGRESS-HF trial was the cleanest test of chronic dosing in heart failure with reduced ejection fraction.

The mean age (standard deviation) of the study population was 65 ± 10 years, 24% were females, and the mean EF was 31% ± 7%. The change in LVESV from baseline to week 4 was not significantly different between elamipretide 4 mg (89.4 mL to 85 mL; difference, -4.4 mL) or 40 mg (77.9 mL to 76.6 mL; difference, -1.2 mL) compared with placebo (77.7 mL to 74.6 mL; difference, -3.8 mL) . The published conclusion was direct: elamipretide was well tolerated but did not improve LVESV at 4 weeks in patients with stable HFrEF compared with placebo .

Reviewers have argued the trial may have been too short. Possibilities to explore include longer therapy duration than the four weeks tested in the PROGRESS-HF trial, since animal-model studies tested three months of Elamipretide therapy, perhaps longer therapeutic durations are required for cardiac remodeling and correction of abnormal mitochondrial dynamics in heart failure. That is a reasonable hypothesis. It is not yet a clinical conclusion. The PROGRESS-HF publication in Journal of Cardiac Failure remains the primary source.

The ophthalmology program has produced similar signals: mechanistically interesting, primary endpoints not met. Although the trial's primary endpoints of mean change in LLVA and GA progression were not met, these analyses were found to be promising and to support and inform the continued development of elamipretide for dry AMD. Phase 3 trials (ReNEW and ReGAIN) are now running.

The honest summary: SS-31 has shown reproducible mechanistic effects on mitochondrial function in humans. It has been associated with functional improvements in narrow disease populations (Barth syndrome, aging skeletal muscle). Studies have shown it has not yet hit primary endpoints in the larger cardiac and ophthalmic indications.

Dosing context (from the clinical record, not from forums)#

Every published human trial of SS-31 has used 40 mg subcutaneous daily as the working dose. The Barth syndrome trial used single daily subcutaneous (SC) doses of 40 mg elamipretide administered for 12 weeks followed by an open-label extension. The ReCLAIM ophthalmology trial used daily subcutaneous elamipretide (40 mg) for 24 weeks in individuals with dry AMD . The PROGRESS-HF trial tested both 4 mg and 40 mg arms.

The most common adverse event is consistent across trials. The most common adverse reactions were injection site reactions which can be treated with oral antihistamines or topical corticosteroids. The PubMed accelerated approval review confirms the same safety signal.

Anyone calculating doses for research applications should use precise reconstitution math rather than online conversion charts. Klarovel's peptide calculator handles concentration, volume, and syringe gradation for any peptide entry, including SS-31.

How SS-31 fits into a mitochondrial longevity stack#

The intellectual appeal of SS-31 is that it acts at a layer most longevity interventions ignore. NAD precursors restore a cofactor. Exercise drives biogenesis. Senolytics clear failing cells. SS-31 stabilises the membrane architecture inside the mitochondria themselves.

That makes it complementary rather than redundant with the rest of the mitochondrial toolkit. Preclinical data points to combined effects with cofactor-based interventions, though no head-to-head human trial has been published. SS-31 does not replace exercise, sleep, or metabolic basics, all of which remain the strongest evidence-backed inputs for mitochondrial health.

Klarovel's protocol layer treats SS-31 as a research-grade option for users who already have the lifestyle fundamentals in place and are working with a clinician. The peptide itself is sourced from third-party suppliers; Klarovel curates the protocol design, dosing logic, and monitoring framework. See how it works for the full model.

The bottom line on SS-31#

SS-31 is the most mechanistically precise mitochondrial peptide in clinical development and the first to win an FDA approval. The cardiolipin-binding mechanism is well-characterised, the Barth syndrome data validates the biology in humans, and the aging-muscle trial provides early support for longevity-adjacent applications. The cardiac and ophthalmic Phase 2 trials missed their primary endpoints, which should temper any oversold benefits while Phase 3 readouts mature. If mitochondrial function is a serious part of your longevity strategy, register for a Klarovel protocol to map SS-31 into a monitored framework, or run the numbers on the peptide calculator before any research-use decision.